



ASX/Media Release

14 October 2015

ASX code: PIQ

Successful completion of Entitlement Issue

Life sciences company Proteomics International Laboratories Ltd (ASX: PIQ) (the Company, PILL) is pleased to announce the successful completion of its fully underwritten non-renounceable entitlement issue to shareholders (**Entitlement Issue**).

The Entitlement Issue closed on Friday 9 October 2015, with 8,065,303 options subscribed for representing a take-up of 63.7% of total options available. A total of 338 shareholders took up their entitlements, raising \$80,653.

In accordance with the ASX Listing Rules Appendix 7A timetable, the Company provides the following break-down of subscriptions to the Entitlement Issue.

Number of securities available under the Entitlement Issue:	12,645,363 options
Number of securities taken up:	8,065,303 options
Shortfall (i.e. securities not taken up):	4,580,060 options

The Entitlement Issue was proposed in the IPO prospectus as a “loyalty option” for those Shareholders who held their issued shares and new shareholders, who were shareholders as at the Record Date, 18 September 2015, for their support of the Company in its first few months after its admission to the Official List of ASX on 16 April 2015.

The Entitlement issue is fully underwritten by K S Capital Pty Ltd. The shortfall will be notified to K S Capital.

PILL is pleased with the response to the Entitlement Issue, and would like to thank all shareholders who participated for their support. The Company continues to advance the execution of its business plans and will keep the market updated on the progress of its Diagnostics, Analytical Services and Drug Discovery business units.

The Company will now proceed to issue the options in accordance with the Entitlement Issue timetable and will provide additional information regarding the Entitlement Issue as required by ASX in due course.

ENDS

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008 Broadway, Nedlands, Perth WA 6009, Australia

T: +61 8 9389 1992 | F: +61 8 6151 1038 | E: enquiries@proteomicsinternational.com | W: proteomicsinternational.com

For personal use only

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
www.proteomicsinternational.com

Media and Investor Inquiries
James Moses
Mandate Corporate
T: +61 420 991 574
E: james@mandatecorporate.com.au

Greg Wood
Managing Director
K S Capital
T: +61 416 076 377
E: g.wood@kscapital.com.au

About Proteomics International Laboratories

PILL is an ASX listed (ASX: PIQ) life science company focused on the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics is an integral part of the biotechnology and life sciences industries and plays a key role in understanding disease and biological systems. It represents a massive global market estimated to be worth \$20.8 billion by 2018.

PILL is recognised as a global leader in its field. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia. The Company's business model uses its proprietary technology platform which operates across three synergistic proteomics-based business units in massive growth markets:

1. **Diagnostics:** Biomarkers of diseases and personalised medicine - focus on diabetic kidney disease and Alzheimer's disease. The biomarkers market is estimated to double in size to \$45.6 billion by 2020.
2. **Analytical services:** Specialist contract research, analytical testing and consultancy - fee for service model.
3. **Drug discovery:** Therapeutic drug discovery with a focus on painkillers and antibiotics. The peptide therapeutics market is currently estimated to be worth \$17 billion.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008 Broadway, Nedlands, Perth WA 6009, Australia

T: +61 8 9389 1992 | F: +61 8 6151 1038 | E: enquiries@proteomicsinternational.com | W: proteomicsinternational.com

For personal use only